Furthermore, studies have shown that the combination of TGF-β inhibitors with imatinib efficiently depleted leukemia-initiating cells and retarded CML development [15]. This evidence concerns the gene TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive.